# Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation

> **NCT00073879** · NA · COMPLETED · sponsor: **Baylor College of Medicine**

## Conditions studied

- Kidney Cancer

## Interventions

- **BIOLOGICAL:** alemtuzumab
- **BIOLOGICAL:** graft-versus-tumor induction therapy
- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine phosphate
- **PROCEDURE:** allogeneic bone marrow transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00073879
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2004-04
- **Final completion:** 2004-04
- **Target enrollment:** — (—)
- **Last updated:** 2015-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00073879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00073879, "Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00073879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*